What is Bicycle Therapeutics plc (BCYC) stock price today?

Bicycle Therapeutics plc (BCYC) is currently trading at $4.22, up 0.24% today.

What is BCYC P/E ratio?

Bicycle Therapeutics plc's P/E ratio is -1.34. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is BCYC return on equity (ROE)?

Bicycle Therapeutics plc's return on equity (ROE) is -35.74%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Bicycle Therapeutics plc's market cap?

Bicycle Therapeutics plc has a market capitalization of $292.84M.

NASDAQ · Biotechnology

Bicycle Therapeutics plc (BCYC) Stock

$4.22 +0.24% NASDAQ: BCYC Healthcare

Valuation

Metric	Value
Price	$4.22
Market Cap	$292.84M
P/E Ratio	-1.34
P/B Ratio	0.53
P/S Ratio	4.61
EPS (TTM)	$-3.16
52-Week High	$9.18
52-Week Low	$3.92
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-35.74%
ROA	-33.57%
ROCE	-40.17%
Gross Margin	-11.86%
Operating Margin	-381.75%
Net Margin	-344.95%
Debt/Equity	0.03
Current Ratio	12.66

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$12.0M	$14.0M	$27.0M	$35.0M	$73.0M
Operating Profit	$-66.0M	$-117.0M	$-190.0M	$-210.0M	$-248.0M
Net Profit	$-67.0M	$-113.0M	$-181.0M	$-169.0M	$-219.0M
EPS	$-2.67	$-3.80	$-5.08	$-2.90	$-3.16
Op Margin	-561.0%	-806.6%	-704.1%	-595.0%	-341.3%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$480.0M	$411.0M	$595.0M	$957.0M	$718.0M
Total Liabilities	$134.0M	$140.0M	$224.0M	$164.0M	$108.0M
Cash	$439.0M	$339.0M	$526.0M	$880.0M	$628.0M
Borrowings	$44.0M	$44.0M	$45.0M	$9.0M	$18.0M

Latest News

Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last? Zacks · Jul 3, 2026 European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading MT Newswires · Jun 30, 2026 European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT Newswires · Jun 17, 2026 European Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading MT Newswires · Jun 16, 2026 European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading MT Newswires · May 22, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-15.0M	$-86.0M	$-61.0M	$-165.0M	$-250.0M
Investing Cash Flow	$-4.0M	$-38.0M	$-6.0M	$-2.0M	$-5.0M
Financing Cash Flow	$7.0M	$1.0M	$1.0M	$8.0M	$0
Net Cash Flow	$303.0M	$-100.0M	$188.0M	$353.0M	$-251.0M
Free Cash Flow	$-17.0M	$-105.0M	$-64.0M	$-166.0M	$-253.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.37
EV / EBITDA	1.19
FCF Yield	-78.20%
Quick Ratio	12.66
Interest Coverage	-1194.08
Return 1Y	-52.24%
Return 3Y	-83.89%
Return 5Y	-87.59%

Ownership

Insiders Held4.49%

Institutions Held73.77%

Institutions Float Held77.23%

Institutional Holder	Shares	Report Date
Baker Bros. Advisors, LP	10,885,357	2026-03-31
FCPM III Services B.V.	3,468,430	2026-03-31
Armistice Capital, LLC	3,398,000	2026-03-31
Long Focus Capital Management, LLC	3,310,687	2026-03-31
Acadian Asset Management. LLC	1,968,025	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ADCTADC Therapeutics SA	$1.59	+11.97%	-2.14	$202.23M	0.00%
CMPXCompass Therapeutics, Inc.	$0.98	-3.59%	-2.06	$177.10M	0.00%
FDMT4D Molecular Therapeutics, Inc.	$12.70	+0.87%	-5.03	$663.91M	0.00%
FULCFulcrum Therapeutics, Inc.	$3.75	+2.18%	-3.05	$286.11M	0.00%
KALV	$27.00	+0.00%	-8.28	$1.44B	0.00%

About Bicycle Therapeutics plc

Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.

Bicycle Therapeutics plc is headquartered in GB.

Bicycle Therapeutics plc (BCYC) stock trades at $4.22 with a market capitalization of $292.84M. The stock is valued at a price-to-earnings (P/E) ratio of -1.34, price-to-book of 0.53, price-to-sales of 4.61. Over the past 52 weeks the stock has ranged between $3.92 and $9.18, and currently trades 54.0% below its 52-week high.

On profitability, Bicycle Therapeutics plc generates a return on equity (ROE) of -35.74%, return on capital employed of -40.17%, an operating margin of -381.75%, a net profit margin of -344.95%.

Official website: www.bicycletherapeutics.com